Fatty Liver and Obstructive Sleep Apnea - Tabular View

Tracking Information
First Received Date ^ICMJE	August 6, 2008
Last Updated Date	August 7, 2008
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE (submitted: August 7, 2008)	Reduction in fatty liver changes on computerized tomography [ Time Frame: Within 1-2 years ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT00730873 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: August 7, 2008)	Improved liver enzymes abnormalities [ Time Frame: Within 1-2 years ]
Original Secondary Outcome Measures ^ICMJE	Same as current

Descriptive Information
Brief Title ^ICMJE	Fatty Liver and Obstructive Sleep Apnea
Official Title ^ICMJE	Fatty Liver and Obstructive Sleep Apnea
Brief Summary	Non-alcoholic fatty liver disease is associated with obstructive sleep apnea. Abnormalities in liver enzymes can improve following continuous positive airway pressure in patients with obstructive sleep apnea. Computerized tomography can be used to quantify fatty liver changes. We hypothesize that continuous positive airway pressure can reduce morphologic fatty liver changes in patients with obstructive sleep apnea and non-alcoholic fatty liver, an that this reduction can be evident using computerized tomography
Detailed Description
Study Phase
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Non-Alcoholic Fatty Liver Disease Obstructive Sleep Apnea
Intervention ^ICMJE	Device: Continuous positive airway pressure
Study Arms / Comparison Groups	Experimental: continuous positive airway pressure
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Obstructive sleep apnea, defined as AHI>5/h Exclusion Criteria: Consumption of more than 20 grams of alcohol per 24 h Known autoimmune disease Usage of known hepatotoxic drugs Medical history positive for viral hepatitis or other chronic liver disease
Gender	Both
Ages	30 Years to 60 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Israel

Administrative Information
NCT ID ^ICMJE	NCT00730873
Responsible Party
Study ID Numbers ^ICMJE	135/07
Study Sponsor ^ICMJE	Assaf-Harofeh Medical Center
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Assaf-Harofeh Medical Center
Verification Date	August 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP